Sciencast Management LP Acquires Shares of 9,630 Hologic, Inc. (NASDAQ:HOLX)

Sciencast Management LP acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 9,630 shares of the medical equipment provider’s stock, valued at approximately $694,000.

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. FMR LLC boosted its holdings in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Boston Partners boosted its holdings in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hologic in the fourth quarter worth approximately $27,007,000. Finally, Swedbank AB boosted its holdings in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Wolfe Research started coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

Hologic stock opened at $61.47 on Friday. The company has a market cap of $13.79 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The firm’s fifty day moving average is $66.06 and its 200 day moving average is $73.99. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.